RTP Mobile Logo
Breast Cancer Update: Surgical Edition, Issue 1, 2011
Released September 2011

Featuring interviews with Drs Eleftherios P Mamounas, Daniel F Hayes, Stephen B Edge and Eric P Winer. (Audio Content)

CE Disclosures and Faculty Information


    Historically, surgery has been the primary mode of treatment for early breast cancer. However, the diagnostic, surgical and medical management of breast cancer has escalated in complexity because of numerous advances in novel technologies and available adjunctive medical therapies. Hence, the multifaceted treatment of breast cancer now requires the input of an interdisciplinary group of expert care providers. This paradigm shift has created the challenge of ensuring that major clinical advances in local and systemic breast cancer therapy are effectively disseminated among all members of the cross-functional team. To bridge the gap between research and patient care, Breast Cancer Update for Surgeons uses one-on-one interviews with leading breast cancer investigators to translate the latest research developments into clinical practice. By providing access to cutting-edge data and expert perspectives, this CME program assists breast surgeons in the formulation of up-to-date clinical management strategies.


    • Use genomic assays to quantify recurrence risk and aid in individualized recommendations for systemic therapy for postmenopausal patients with node-negative or node-positive, ER-positive breast cancer.
    • Evaluate issues related to the accuracy, reliability and interpretation of the ER and HER2 status of breast tumors in the context of local laboratory practices and national guidelines.
    • Formulate an evidence-based approach to the surgical management of patients with a positive sentinel lymph node biopsy.
    • Assess long-term outcomes with magnetic resonance imaging and screening compared to prophylactic mastectomy for women with BRCA mutations and family history of premenopausal breast cancer.
    • Develop an approach to monitor and facilitate patient adherence to orally administered antineoplastic therapies.
    • Counsel appropriately selected patients about the option of participating in ongoing clinical trials.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Edge had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr MamounasAdvisory Committee: Genomic Health Inc, Novartis Pharmaceuticals Corporation; Consulting Agreement: Genomic Health Inc; Speakers Bureau: Celgene Corporation, Genomic Health Inc. Dr HayesConsulting Agreements: BioMarker Strategies, Chugai Pharmaceutical Co Ltd; Paid Research: Novartis Pharmaceuticals Corporation, Pfizer Inc, Veridex LLC; Patent: Immunicon Corporation; Stock Ownership: Oncimmune Ltd. Dr WinerAdvisory Committee: Novartis Pharmaceuticals Corporation.

    Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Genomic Health Inc.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: September 2011
    Expiration date: September 2012

Acknowledge and close

Listen to audio:
Breast Cancer Update: Surgical Edition, Issue 1, 2011
Released September 2011

Featuring interviews with Drs Eleftherios P Mamounas, Daniel F Hayes, Stephen B Edge and Eric P Winer. (Audio Content)

Read print: